ArticleBlood advances2024
Transfusion needs after CAR T-cell therapy for large B-cell lymphoma: predictive factors and outcome (a DESCAR-T study).
Article in Blood advances, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 23 citations in OpenAlex.
- CAR-HEMATOTOX score as a predictor of hematotoxicity, infection, and survival after CAR T-cell therapy in hematologic malignancies: a systematic review and meta-analysis.Frontiers in oncology · 2026Pooled it
- Disseminated intravascular coagulation in chimeric antigen receptor T-cell therapy: a 6-year nationwide analysis of clinical outcomes and health care resource utilization in patients with hematologic malignancies.Research and practice in thrombosis and haemostasis · 2026Article
- Late phase transfusion after CAR T therapy is associated with persistent hematotoxicity and non-relapse mortality in multiple myeloma: a post hoc analysis.BMC medicine · 2026Article
- Early CAR T-cell therapy in relapsed/refractory large B-cell lymphoma is associated with lower hematotoxicity burden.Blood advances · 2026Article
- Late hematologic toxicity after CAR T-cell therapy in large B-cell lymphoma: incidence, risk factors, and clinical impact.Bone marrow transplantation · 2026Article
- Engineering Immunity: Current Progress and Future Directions of CAR-T Cell Therapy.International journal of molecular sciences · 2026Review
- Time-Series Clustering Captures Patterns of Early Immune Effector Cell-Associated Hematotoxicity That Are Predictable Using Tree-Based Models.JCO clinical cancer informatics · 2026Article
- Platelet Transfusion for Patients with Cancer: An Update.Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie · 2025Review
- Population-based validation of the CAR-HEMATOTOX for hematotoxicity, infections, and survival after CART in R/R LBCL.Blood advances · 2025Article
- Clonal Hematopoiesis and Inflammation Predict Hematologic Toxicity and Secondary Myeloid Malignancies after B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T-cell Therapy.Clinical cancer research : an official journal of the American Association for Cancer Research · 2025Article
- Deciphering the Complex Intertwining Between Cytopenia and Transfusion Needs After CAR-T-Cell Therapy for B-Cell Malignancies.Life (Basel, Switzerland) · 2025Article
- Observational
- Rising transfusion rates amidst stable blood supply: A Canadian perspective on emerging challenges for blood operators.Transfusion · 2025Article
- Noncanonical and mortality-defining toxicities of CAR T cell therapy.Nature medicine · 2025Review
- Immune effector cell-associated hematotoxicity: mechanisms, clinical manifestations, and management strategies.Haematologica · 2025Review
- Development and validation of predictive models of early immune effector cell-associated hematotoxicity.Blood advances · 2025Article
- Delayed neutrophil recovery following BCMA CAR-T therapy in Duffy-null myeloma does not impact severe infections or survival.Blood advances · 2025Article
- Development and validation of an automated computational approach to grade immune effector cell-associated hematotoxicity.Bone marrow transplantation · 2024Article
- Immune effector cell-associated haematotoxicity after CAR T-cell therapy: from mechanism to management.The Lancet. Haematology · 2024Review
- Navigating the prognostic role of transfusions after CAR-T.Blood advances · 2024Article
Corrections and comments
- Commented on by
Authors and funding
22 authors at 19 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
abstractChimeric antigen receptor (CAR) T-cells targeting CD19 have been approved for the treatment of relapse/refractory large B-cell lymphoma. Hematotoxicity is the most frequent CAR T-cell-related adverse event. Transfusion support is a surrogate marker of severe cytopenias. Transfusion affects patients' quality of life, presents specific toxicities, and is known to affect immunity through the so-called transfusion-related immunomodulation that may affect CAR T-cell efficacy. We analyzed data from 671 patients from the French DESCAR-T registry for whom exhaustive transfusion data were available. Overall, 401 (59.8%) and 378 (56.3%) patients received transfusion in the 6-month period before and after CAR T-cell infusion, respectively. The number of patients receiving transfusion and the mean number of transfused products increased during the 6-month period before CAR T-cell infusion, peaked during the first month after infusion (early phase), and decreased over time. Predictive factors for transfusion at the early phase were age >60 years, ECOG PS ≥2, treatment with axicabtagene ciloleucel, pre-CAR T-cell transfusions, and CAR-HEMATOTOX score ≥2. Predictive factors for late transfusion (between 1 and 6 months after infusion) were pre-CAR T-cell transfusions, CAR-HEMATOTOX score ≥2, ICANS ≥3 (for red blood cells [RBC] transfusion), and tocilizumab use (for platelets transfusion). Early transfusions and late platelets (but not RBC) transfusions were associated with a shorter progression-free survival and overall survival. Lymphoma-related mortality and nonrelapse mortality were both increased in the transfused population. Our data shed light on the mechanisms of early and late cytopenia and on the potential impact of transfusions on CAR T-cell efficacy and toxicity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.